Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: An open-label, phase 2 trial

The Lancet Oncology

Volumn 15, Issue 12, 2014, Pages 1311-1318

  Fowler, Nathan H ^a   Davis, R Eric ^a   Rawal, Seema ^a   Nastoupil, Loretta ^a   Hagemeister, Fredrick B ^a   McLaughlin, Peter ^a   Kwak, Larry W ^a   Romaguera, Jorge E ^a   Fanale, Michelle A ^a   Fayad, Luis E ^a   Westin, Jason R ^a   Shah, Jatin ^a   Orlowski, Robert Z ^a   Wang, Michael ^a   Turturro, Francesco ^a   Oki, Yasuhiro ^a   Claret, Linda C ^a   Feng, Lei ^a   Baladandayuthapani, Veerabhadran ^a   Muzzafar, Tariq ^a   Tsai, Kenneth Y ^b   Samaniego, Felipe ^a   Neelapu, Sattva S ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Health Science Center at Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW BIOPSY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; EYE IRRITATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFUSION RELATED REACTION; LUNG DISEASE; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; MEMORY DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; RASH; RESPIRATORY DISTRESS; THROMBOCYTOPENIA; THROMBOSIS; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RITUXIMAB; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84908574357     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70455-3     Document Type: Article

References (42)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997, 89:3909-3918. The Non-Hodgkin's Lymphoma Classification Project.
2. Zelenetz A, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma. Version 1 (accessed July 3, 2014). http://wwwnccnorg/professionals/physician_gls/pdf/nhlpdf.
3. Freedman A Follicular lymphoma: 2012 update on diagnosis and management. Am J Hematol 2012, 87:988-995.
4. Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011, 118:3489-3498.
5. Chen CI, Bergsagel PL, Paul H, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 2011, 29:1175-1181.
6. Kiesewetter B, Troch M, Dolak W, et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica 2013, 98:353-356.
7. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4952-4957.
8. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009, 145:344-349.
9. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011, 22:1622-1627.
10. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006, 108:618-621.
11. Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008, 14:4650-4657.
12. Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009, 114:4713-4720.
13. Chanan-Khan AA, Chitta K, Ersing N, et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol 2011, 155:457-467.
14. McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol 2012, 2012:513702.
15. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008, 140:36-45.
16. Yang Y, Shaffer AL, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012, 21:723-737.
17. Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol 2014, 164:811-821.
18. Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014, 343:301-305.
19. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014, 343:305-309.
20. Stewart AK Medicine. How thalidomide works against cancer. Science 2014, 343:256-257.
21. Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009, 84:553-559.
22. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008, 26:4579-4586.
23. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-3732.
24. Cheson BD, Leonard JP Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008, 359:613-626.
25. Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013, 27:1902-1909.
26. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012, 13:716-723.
27. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007, 25:571-578.
28. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
29. Thall PF, Simon RM, Estey EH Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 1995, 14:357-379.
30. Thall PF, Simon RM, Estey EH New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol 1996, 14:296-303.
31. Thall PF, Sung HG Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat Med 1998, 17:1563-1580.
32. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004, 104:1258-1265.
33. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997, 15:1110-1117.
34. Figaro MK, Clayton W, Usoh C, et al. Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review. Am J Hematol 2011, 86:467-470.
35. Tusher VG, Tibshirani R, Chu G Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121.
36. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge- based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550.
37. Colombat C, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001, 97:101-106.
38. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005, 23:1103-1108.
39. Martin P, Jung S, Johnson J, et al. CALGB 50803(Alliance): a phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Hematol Oncol 2013, 31(suppl 1):063. (abstr).
40. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013, 381:1203-1210. on behalf of the Study group indolent Lymphomas.
41. Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013, 31:1506-1513.
42. Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012, 159:154-163.